Olink Holding AB (publ), trading on Nasdaq under the symbol OLK, has announced that Novogene Asia Pacific Middle East and Africa (AMEA) has incorporated the Olink Explore HT platform to offer advanced next-generation proteomics technology to the scientific community in the region.
This strategic addition enhances the multi-omics research services provided by Novogene AMEA, offering researchers valuable insights and advancing disease biology understanding.
Read also: Afya Rekod and Medi-Science Partner on Kenyan Healthtech Delivery
Leveraging Cutting-Edge Proteomics Technology
Olink’s Explore HT platform represents the latest in next-generation proteomics technology. It empowers scientists to accurately measure over 5,400 proteins using just 2µl of sample. This combination of Olink’s PEA technology with next-generation sequencing (NGS) readout enhances specificity and sensitivity, providing unmatched precision and sensitivity.
By integrating Olink Explore HT with their existing genomics, transcriptomics, metagenomics, and epigenomics capabilities, Novogene AMEA aims to deliver comprehensive multi-omics solutions to the scientific community. This alignment allows researchers to unlock a new layer of actionable data, leading to more impactful discoveries in disease biology.
Quotes from Key Stakeholders
Justin Lee, Vice President of Novogene AMEA, highlighted their commitment to delivering cutting-edge multi-omics solutions in the Asia Pacific, Middle East, and Africa region. The incorporation of Olink’s proteomics technology into their services allows for the integration of multi-omics data, offering extraordinary insights into disease biology and paving the way for impactful discoveries.
Andrea Ballagi, MD, PhD, Vice President Sales and Marketing Asia and Pacific Region at Olink Proteomics, expressed their pleasure in seeing Olink Explore HT used by Novogene to provide innovative research services. This collaboration strengthens their ability to support research across various therapeutic research fields and advance the understanding of human biology for future healthcare improvements.
Empowering Proteomics at Scale
Olink’s proteomics solutions are designed to unlock the immense potential of proteomics across various scales. Researchers around the world have used Olink’s technology across a wide range of therapeutic areas to gain a deeper understanding of molecular pathways involved in the development, progression, and outcome of diseases. Olink Explore HT now allows Novogene AMEA to offer high-throughput proteomics with leading specificity, enabling their customers to explore the intricate connections between genes, proteins, and diseases.
The Promise of Multi-Omics
This collaboration exemplifies the growing interest in multi-omics research and its potential for driving groundbreaking discoveries in healthcare. The integration of genomics, transcriptomics, metagenomics, epigenomics, and proteomics provides researchers with a holistic view of biological processes and diseases.
CloudClinic unveils tech-enabled healthcare platform in Nigeria
About Olink Holding AB (publ)
Olink Holding AB (publ) is dedicated to accelerating proteomics alongside the scientific community across multiple disease areas, enabling new discoveries and improving patients’ lives. Olink provides a platform of products and services used by leading pharmaceutical companies, clinical institutions, and academic organizations to deepen the understanding of real-time human biology and advance 21st-century healthcare. The company was founded in 2016 and has a strong presence in Europe, North America, and Asia, with its headquarters in Uppsala, Sweden.
Forward-Looking Statements
This press release contains forward-looking statements based on management’s beliefs, assumptions, and available information. These forward-looking statements are expressed or implied in the document. Actual results may significantly differ from the information expressed or implied in these statements. Various factors may influence these statements, and they are subject to risks, uncertainties, and other factors described in the company’s filings with the Securities and Exchange Commission. The company does not undertake any obligation to update forward-looking statements, except as required by law.